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1. Introduction 
myo-Inositol (hexahydroxycyclohexane) has long 
been known as one of the important growth-pro- 
moting chemicals for the living cells. A number of 
reports have suggested its importance in micro-organ- 
isms [l-3], plant cells and tissues in culture [4], 
mammalian cells [S] and animals [6]. As phospho- 
monoester, myo-inositol serves as precursor for 
phytic acid [7-l 11, an important phosphate reserve 
in plants, which on hydrolysis provides inorganic 
phosphate and carbon skeleton necessary for the 
growth of the germinating seed [12,13]. In addition, 
its involvement as a lipotropic factor [ 14-161, as 
cofactor of enzymes and mitochondrial functions 
[ 17 ,181 and mediators of cellular responsiveness as 
phosphoinositides [19] have long been recognized. 
Since G-6-P, the only known de novo precursor of 
myo-inositol, is the pivotal metabolite for essential 
cellular functions, a competition for substrate is 
always in operation between myo-inositol synthesis 
and other pathways of utilisation of G-6-P. A precise 
control over this competition would be necessary to 
enable a cell to have uniform utilization for the two 
sets of pathways for synthesis of an adequate amount 
of myo-inositol, a compound of vital importance for 
cell survival. 
How does the living cell accomplish this? Based 
mostly on biochemical and genetic studies with myo- 
inositol-deficient systems, a model is proposed here 
suggesting a coupled operation of the gluconeogenic 
enzyme, fructose 1,6_bisphosphatase and myo-inositol 
synthase, as the probable regulatory event for cell 
survival under conditions of myo-inositol deficiency. 
Deficiency of this compound induces remarkable 
changes in the metabolic makeup of the cell, mani- 
fested in the abnormal accumulation of lipids [20], 
alterations of sugar transport [21], and changes in the 
membrane structure and properties [22,23]. Acute 
starvation for myo-inositol has been reported to lead 
to loss of cell viability, a phenomenon known com- 
monly as ‘inositol-less death’ [22-241. 
2. Induction of myo-inositol deficiency and 
biochemical changes associated with it 
Synthesis of myo-inositol from its precursor glu- 
cose 6-phosphate (G-6-P) is accomplished by an 
enzyme system L-myo-inositol 1 -phosphate synthase 
(myo-inositol synthase, EC 5.5 .1.4) and by the specific 
L-myo-inositol 1 -phosphatase. Though reported from 
numerous sources, e.g., animal, plant and microbial, 
complete purification of myo-inositol synthase from 
animal sources [25,26] and Saccharomyces cerevisiae 
[27] has only recently been achieved. The reaction 
mechanism of the enzyme, an internal oxidoreductase 
requiring NAD, is yet to be determined in detail. 
One classical approach for establishing the essen- 
tiality of a nutrient is to deplete the system of the 
nutrient in question and study the biochemical 
changes associated with it in the deficient cells. Such 
studies for myo-inositol are discussed below. 
2.1. Deficiency induced by nutrient manipulation 
Depletion of myo-inositol in a system may be 
achieved by feeding an animal with a myo-inositol- 
free diet or growing cells in synthetic media without 
inositol. Care must be taken so that the special dietary 
condition does not cause any complicated metabolic 
disorder unrelated to myo-inositol deficiency. Ani- 
mals fed with a myo-inositol-deficient diet developed 
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acute lipodystrophy, which can be corrected by myo- 
inositol supplementation [14,28,29]. Lactation- 
induced fatty liver formation was discovered in [30] 
while studying the effect of myo-inositol deprivation 
in pregnant and lactating rats, which was prevented 
by dietary supplementation or termination of lacta- 
tion. It was concluded [30] that a possible threshold 
level of free myo-inositol (-0.15 pmol/g lipid free tis- 
sue) is required to prevent fatty liver formation in 
this system. In [20,3 l] neutral lipid accumulation in 
rat liver was demonstrated by induction of dietary 
myo-inositol deficiency within a short period of time 
without interfering with the growth of the experi- 
mental animal. 
The biochemical mechanism underlying neutral 
lipid accumulation in myo-inositol-deficient Succha- 
romyces carlsbergensis has been detailed in [32]. In 
these cells grown in glucose, myo-inositol deficiency 
induced a cellular increase in fructose 1,6-bisphosphate 
(Fru-P,) and a lower citrate level resulting in an 
enhancement of the acetyl CoA carboxylase activity 
concomitant with the accumulation of neutral lipids 
[32]. The involvement of Fru-P, in this phenomenon 
was observed in [33,34] showing that no lipid accu- 
mulation was observed when myo-inositol-deficient 
cells of Saccharomyces carlsbergensis are grown with 
ethanol, glycerol or lactate as carbon source. Most 
likely, use of these carbon sources activated the glu- 
coneogenic enzymes like Fru-P,ase resulting in a drop 
of cellular FruP, followed by subsequent loss of lipid 
accumulation. 
2.2. Induction of deficiency by genetic means 
Because of endogenous synthesis, induction of 
myo-inositol deficiency by nutrient manipulation can 
not make an organism auxotrophic for it. Ideally, this 
may be obtained by inducing mutations at the myo- 
inositol synthase gene locus. This was achieved in 
[24] raising 52 inositol-requiring mutants in Skcha- 
romyces cerevisiue by treatment with ethyl methane 
sulfonate. These mutants fall into 10 independent 
genetic loci designated ho-1 - irzo-10. Of the mutants, 
36 behave as alleles of the ino-l locus (the structural 
gene for inositol synthase [27]; fully characterized 
[35]). Under conditions of inositol starvation, all the 
representative mutants (with the exception of the 
class V mutant) exhibit dramatic loss of cell viability 
(inositol-less death) which can be prevented by inosi- 
to1 supplementation or by disruption of protein syn- 
thesis by cycloheximide [24]. Complete abolition of 
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inositol synthesis by mutagenesis was not possible in 
this organism and the mutants exhibited a spectrum 
of residual synthase activity, from 0.004% to -2.5% 
that of the wild-type [36]. However, these mutants 
are potential tools for studying the biochemical lesions 
originating from inositol starvation. Similar mutant 
cell lines have been reported from animal sources 
[37,38]. 
3. The yeast inositol auxotroph, ino 5-12 
Of the 10 different classes of mutants isolated in 
[24], the mutant ino 5-12, the only representative of 
the complementation class V, exhibits some unique 
characteristics [24] which can be summarized as fol- 
lows: 
(i) While all the other ino-mutants grow on glucose, 
this mutant grows on ethanol or glycerol and glu- 
cose exerts inhibitory effects on its growth. 
(ii) The residual inositol synthase activity of irzo 5-12 
is highest among all the mutants and is -2.5% 
that of the wild-type. 
(iii) Though an inositol auxotroph, this mutant does 
not exhibit the ‘inositol-less death’ characteristic 
of all the other ino mutants. 
The inability of ino 5 -12 to grow on glucose may 
be explained as due to (i) defects in the glucose trans- 
port system and/or (ii) lack of hexokinase/glucokinase 
activity. However, this does not explain the inhibi- 
tory effect of glucose on its growth or its capability 
to grow on ethanol or glycerol. Though not yet veri- 
fied experimentally, it is more likely that the mutant 
is a gluconeogenic organism and that the glucose 
effect, in fact, reflects the known catabolite inactiva- 
tion of the gluconeogenic enzymes of the system 
[39-421. Prevention of ‘inositol-less death’ in this 
mutant without external supplementation suggests 
that the residual synthase activity provides the 
required amount of inositol necessary for survival. 
4. Mammalian brain Fru-P,ase: Probable relation with 
regulation of inositol synthesis 
From sections 2.1 and 2.3 it becomes apparent 
that Fru-Pz and the gluconeogenic enzyme Fru-P,ase 
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have some relation to the inositol biosynthetic reac- 
tions. A similar phenomenon had been observed during 
our investigations on the phospholipid-mediated 
G-6-P accumulation in a low-speed supernatant of rat 
brain [43]. The locus of this phospholipid effect was 
delineated at the fructose phosphate interconversion 
step leading subsequently to the discovery of Fru- 
P,ase in this nongluconeogenic organ [44]. The 
unequivocal demonstration of Fru-Pzase in brain was 
later confirmed in [45]. However, the physiological 
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role played by this enzyme in brain is open to specu- 
lation. It has been suggested [43] that this enzyme 
may have a regulatory role in brain inositol synthesis. 
Mammalian brain is estimated to have a high titre of 
free myo-inositol (-5-8 mM), half of which is 
enzymatically synthesized in situ [46,47]. Since this 
organ is essentially a glycolytic one [48], a control 
mechanism in the utilization of G-6-P is expected to 
operate for providing sufficient precursor for this 
high rate of synthesis. The accumulation of G-6-P, by 
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Fig.1. Probable vents related to the postulated ‘normal’ (--- ) and ‘rescue’ (---) synthesis of myo-inositol. Numbers in paren- 
thesis indicate enzymes of the reactions as follows: (1) myo-inositol synthase; (2) myo-inositol l-phosphatase; (3) phosphohexo- 
isomerase; (4) phosphofructokinase; (5) fructose 1,6_bisphosphatase. 
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a reciprocal phospholipid effect on the phosphofruc- 
tokinase (inhibition)/Fru-P,ase (stimulation) system, 
may be the ideal regulatory mechanism by which this 
may be achieved. The Fru-P,ase by itself may thus be 
responsible for sequestering G-6-P for synthesis of 
myo-inositol at a time of cellular demand. 
5. ‘Rescue synthesis’ of myo-inositol: The model 
The proposed model for coupling between Fru- 
P,ase and myo-inositol synthase visualizes two 
distinctly different pools of G-6-P in a cell for utiliza- 
tion as myo-inositol precursor (fig.1). The first one 
(designated G-6-P. I) contributing the major (95597%) 
cellular myo-inositol may be derived from usual sub- 
strates like glucose, glycogen etc; this synthesis may 
be termed ‘normal synthesis’. The second pool of 
G-6-P (designated G-6-P. II) derived entirely from glu- 
coneogenic substrates or others via Fru-P,, synthesizes 
a minor (max. 3-5%) portion of myo-inositol, vital 
for cell survival and/or prevention of lipid accumula- 
tion under conditions of inositol starvation. It is this 
second type of synthesis to which I would like to 
ascribe the term ‘rescue synthesis’ which would require 
a coordinate operation of FruP,ase and myo-inositol 
synthase. 
The suggestive participation in brain of Fru-P,ase 
in regulation of inositol synthesis may in fact, be 
related to this phenomenon of ‘rescue synthesis’. It 
may be argued that at a time of cellular demand this 
enzyme in brain may be called upon for rerouting the 
G-6-P from the first pool (i.e., G-6-P. I) to the second 
pool (i.e., G-6-P. II) via FruPz for utilization solely as 
myo-inositol precursor. 
Furthermore, in myo-inositol-deficient Saccharo- 
myces carlsbergensis grown in ethanol [33,34], the 
mechanism of prevention of lipid accumulation might 
involve an activation of FruPzase coupled to produc- 
tion of threshold-level of myo-inositol by ‘rescue syn- 
thesis’. 
Experimental verification of the proposed cou- 
pling between Fru-P,ase and inositol synthase might 
necessitate combined genetic and biochemical studies. 
To this end, the yeast mutant ino 5-l 2, with its unique 
properties already discussed, meets all requirements 
for potential test organism. The inositol synthase in 
this mutant produces -2.5% of cellular inositol com- 
pared to that of the wild-type yeast [36] an amount 
ofinositol obviously sufficient to maintain conditions 
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for cell-survival, and may be considered as an estimate 
of ‘rescue synthesis’ in this organism. In accordance 
with the proposed model, the mutant ino 5-l 2 may 
be viewed as an organism in which the postulated ‘nor- 
mal synthesis’ is entirely missing due to mutagenesis 
and the mutant survives by virtue of ‘rescue synthesis’ 
only. The synthase in ino 5-l 2 (the ‘rescue synthase’?) 
thus may turn out to be an enzyme quite different 
from the wild-type synthase (the ‘normal synthase’?). 
An inkling of this suggestion is found in the observa- 
tion that, when challenged against the antibody raised 
against the purified wild-type inositol synthase, 
extracts of ino 5-l 2 failed to show any detectable 
cross-reactive -62 OOOM, protein, the characteristic 
monomer of the wild-type synthase. This sensitive 
immunoprecipitation technique has been successfully 
employed for identification of the structural gene for 
inositol synthase [27] and for screening a large num- 
ber of inositol mutants of Saccharomyces cerevisiae 
[35,49]. This finding, by itself, is suggestive of a mul- 
tiple nature of the enzyme in yeast presumably 
designed for two different physiological functions. 
Complete elucidation of the mechanism underlying 
the proposed hypothesis would require a rigorous bio- 
chemical as well as genetic analysis of the yeast 
mutant ino 5-l 2, probably the best-suited organism 
for this purpose. 
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